Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Reuters

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Chicago Sun-Times

Fears of 'chemist deserts' in areas where a third of pharmacies have shut in six years

New data reveals Bristol East, Bradford West, Pendle, Torbay and Hove are among the areas to have lost the largest numbers of pharmacies in the last few years

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

COVID-19 vaccine sales push Moderna past expectations in Q2

Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts

The Independent UK

Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet

Consumer goods spin-off makes few waves in biggest European listing for more than a decade

The Guardian - UK

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

US allows pharmacists to prescribe Pfizer's COVID pill

U.S. pharmacists can now prescribe the leading COVID-19 pill directly to patients

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Moderna confirms two-in-one Covid and flu jab in the works as testing under way

Scientists have developed an alternative to the current separate inoculations with the trial already under

Daily Record

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Reuters

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

Tentative $161.5 million settlement reached in opioid trial

Attorneys for the state of West Virginia and two remaining pharmaceutical manufacturers have reached a tentative $161.5 million settlement

The Independent UK

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

Benzinga

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Axios

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Asharq Al-Awsat

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

AAP

CSL profit falls due to pandemic curbs

Blood products giant CSL says that its ability to collect plasma has been improving as social mobility increases.

Los Angeles Times

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Salon

Drug industry dollars flow into congress

KHN's Pharma Cash to Congress database reveals how the drug industry attempts to influence politics

Tribune News Service

Pharma campaign cash delivered to key lawmakers with surgical precision

The Biden administration and Congress are embroiled in high-stakes haggling over what urgent priorities will make it into the ever-shrinking social spending bill. But for the pharmaceutical industry there is one agenda: Heading off Medicare drug price negotiation, which it considers an existential threat to its business model.

Evening Standard

Portugal scraps quarantine for Brits who had Indian-made Astra Zeneca jab

Portugal is expected to lift quarantine requirements for Britons who have had an Indian-made AstraZeneca vaccine.

ABC News

WA Premier says under-40s should not get Astra Zeneca based on expert health advice

WA Premier Mark McGowan joins Queensland Premier Annastacia Palaszczuk in saying people under 40 should not get the AstraZeneca COVID vaccination, based on health advice.

1 … 140 141 142 143

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.